Company Overview
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -54.56% |
| 6 Months: | -63.55% |
| 3 Months: | -53.56% |
| 1 Month: | +1.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 75.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FULC Fulcrum Therapeutics, Inc. R2K | 3.59 | -3.12 | $239.21M | 0.00% | -24.00% | -27.10% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 750.00K | 2.00M | 1.85M | 4.79M | 4.38M | 4.93M | 2.59M | 1.88M | 1.18M | 295.00K | 880.00K | 759.00K | 0 | 80.00M | 0 | - | 0 | 0 | - |
| Operating Income | - | -7.85M | -9.09M | -37.23M | -13.49M | -17.01M | -18.80M | -15.92M | -19.10M | -17.04M | -19.68M | -20.77M | -26.00M | -34.23M | -24.36M | -27.94M | -27.29M | -27.44M | -29.83M | 52.49M | -25.13M | -20.40M | -19.82M | -21.86M | -22.19M |
| Net Income | -6.94M | -7.85M | -8.94M | -36.84M | -13.17M | -16.54M | -18.45M | -15.69M | -18.96M | -17.00M | -19.65M | -20.72M | -25.93M | -34.07M | -23.74M | -24.78M | -23.78M | -24.02M | -26.87M | 55.41M | -21.70M | -17.66M | -17.30M | -19.59M | -18.89M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.60 | -0.57 | -0.64 | -0.83 | -0.51 | -0.41 | -0.38 | -0.39 | -0.43 | 0.87 | -0.35 | -0.28 | -0.28 | -0.31 | -0.25 |
| R&D Expense | - | 5.79M | 6.96M | 34.63M | 10.86M | 13.50M | 14.48M | 12.78M | 15.64M | 16.33M | 17.38M | 17.08M | 17.83M | 25.02M | 15.37M | 16.71M | 17.85M | 18.24M | 19.77M | 17.26M | 14.64M | 13.40M | 12.99M | 14.30M | 14.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 8.82M | 19.16M | 6.34M | 2.81M | 80.00M | 0 |
| Operating Income | -33.50M | -84.22M | -71.61M | -81.05M | -112.56M | -110.66M | -21.90M | -84.77M |
| Net Income | -32.59M | -82.68M | -70.82M | -80.85M | -109.87M | -97.33M | -9.72M | -74.88M |
| Diluted EPS | - | - | - | -2.29 | -2.44 | -1.59 | -0.16 | -1.18 |
| R&D Expense | 25.18M | 71.07M | 59.04M | 69.70M | 76.78M | 71.80M | 63.39M | 56.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 85.77M | 110.44M | 129.58M | 235.00M | 226.69M | 257.69M | 260.72M | 366.28M |
| Total Equity | -33.27M | -63.67M | 87.15M | 95.18M | 211.54M | 198.94M | 235.19M | 243.03M | 349.00M |
| Cash & Equivalents | - | 72.80M | 96.71M | 57.05M | 35.41M | 35.10M | 25.56M | 58.21M | 197.53M |
| Total Liabilities | - | 9.77M | 23.29M | 34.40M | 23.46M | 27.74M | 22.50M | 17.68M | 17.28M |
| Current Liabilities | - | 4.23M | 12.14M | 26.73M | 19.20M | 16.73M | 13.68M | 11.04M | 13.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.56M | -39.48M | -53.66M | -78.48M | -97.05M | -90.97M | -2.22M | -60.06M |
| Investing Cash Flow | -8.98M | -944.00K | -57.14M | -129.67M | 12.41M | -36.69M | 32.23M | 30.72M |
| Financing Cash Flow | 105.03M | 64.34M | 71.13M | 186.51M | 84.32M | 118.12M | 2.75M | 168.67M |
| Capital Expenditure | -8.98M | -853.00K | -1.34M | -1.71M | -1.96M | -508.00K | -278.00K | -314.00K |
| Free Cash Flow | -31.54M | -40.34M | -55.00M | -80.19M | -99.01M | -91.47M | -2.50M | -60.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -811.6% | -423.0% | -1,774.9% | -3,945.2% | -27.4% | - |
| Net Margin % | - | - | -802.7% | -421.9% | -1,732.4% | -3,470.1% | -12.2% | - |
| ROE % | 51.2% | -94.9% | -74.4% | -38.2% | -55.2% | -41.4% | -4.0% | -21.5% |
| ROCE % | -41.1% | -85.7% | -69.6% | -37.6% | -53.6% | -45.4% | -8.8% | -24.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.85% | 6.56M | $24.11M |
| 2 | RA Capital Management, L.P. | 9.09% | 6.05M | $22.25M |
| 3 | Blackrock Inc. | 8.09% | 5.39M | $19.81M |
| 4 | TCG Crossover Management, LLC | 7.88% | 5.25M | $19.29M |
| 5 | Braidwell LP | 4.70% | 3.13M | $11.52M |
| 6 | Nantahala Capital Management, LLC | 4.58% | 3.05M | $11.21M |
| 7 | Vanguard Capital Management LLC | 4.04% | 2.69M | $9.90M |
| 8 | Siren, L.L.C. | 3.53% | 2.35M | $8.64M |
| 9 | First Turn Management, LLC | 3.39% | 2.26M | $8.29M |
| 10 | Aberdeen Group plc | 3.32% | 2.21M | $8.13M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FULC
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQclJaelEycVNOVUcyeW5HdDVrdEZ3VjU1MU1iM1ZDNkZoUHlid3lJeEYwT21IOXNzRG5kNElKbUZKNkh3ZE9ncGRPdExsaXFqQ0FBcDFELTJNVHYyZ3lXSlcwSXpxNHlWWktpV2VHNHlEZzAwT0dBUWdHQXZkdjhvOUp6QlNHUmRoNWN0dj…
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPY2phNGpCanBVS2lEZllvYWkwR0gwMmlfTEhMRnZNdEdwd0VnbDRIVHJuOWVsb2d1dC1PYWpKY1lVc05GZXhuVlV3Y3RwRU1IN2FBVnpnRVE2N2ZmSS0zcTRVZzhWbTJ5TllJLTM0LUV1Mml3Z2h3OXhvamlRdHhLbHBROVN3U3pJTEdFNX…
Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNWlpwaGJvN2ZfMi1MMzZUS0dlWW00UGJranVaWHpySGU1VzkxZXJrZHR6RnlFcUp3NTZJeGdSR1JHdGd2VXQ5YjZJTXlVd3lKNWY1V2F5MU9OU2tQd1lrOF83TTQ3U0YxWVF1UWxieHNWbDh0MlU3dlJZSGVWRnJmVzUyTjd1TEhET3pYNE…
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPZWlhSWJBczRUS1EzLVlvaldmamFnWlN5OEJua0YtcG9Ka2Q5SjNQcVQ3OE9DaGl2aGxDUVNjVk96ZTVYSUdrUi1GVVhZb0YzcWk0bXplX3hoelNQdXFhZ0lHYW9qNHJoWjdacHlIUGthZ0pCX2RWS3lIaTZYMzVNb0Y5X3lfV0p3LXJkN0…
Fulcrum Therapeutics stock plunges 30% on program discontinuation - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOc0Y3TjV1b2ZlVGZ2Vl9BUGtHR0xILVBIZzcxTm51eWh5cktJTmhXWk5pZHdvT3dOdGpkM2UxQndXWGhwZ0g3WU5VM2Q2XzNVRkpfRk5RYlVKZndOaUN0dGtNNHBpQUVVLTNZSUN0MUwyWHVDcHdfcmNfdGk4cEZvb2kwRGtkb1FNZnNMRE…
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud - Business Wire
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxOc1BtTTdzWlRRd3JFVFdmYVBlU0VhWXctQmowbEtlRU95Mzdrdy1jeEdjMF9OUHNRZWNsM3E3cl9QcUxETW5xUThRREV1aDlYd0M3Y1liX1QwSHNhMGY5RTFMSG00czBjYWczWVRMRHZkY3A1MnFGUmdvN0hWMk5aRDZjdG1CNUNDYzNTZz…
FULC — Frequently Asked Questions
What is the current share price of Fulcrum Therapeutics, Inc. (FULC)?
As of 2026-07-14 21:23 PDT, Fulcrum Therapeutics, Inc. (FULC) trades at $3.59 on NasdaqGM. Its 52-week range is $3.14 to $14.60.
What is the market capitalisation of FULC?
Fulcrum Therapeutics, Inc. (FULC) has a market capitalisation of $239.21M on NasdaqGM.
What is the P/E ratio of FULC?
FULC trades at a trailing price-to-earnings (P/E) ratio of -3.12. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.69.
What is the return on equity (ROE) of FULC?
FULC has a return on equity (ROE) of -27.10%. Its return on capital employed (ROCE) is -24.00%.
Is FULC a good stock to buy?
This page provides a data-driven analysis of Fulcrum Therapeutics, Inc. (FULC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.